Menu
Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 12 » default
Pharmacogenomics and Personalized Medicine
ISSN: 1178-7066
- View all (571)
- Volume 16, 2023 (47)
- Volume 15, 2022 (82)
- Volume 14, 2021 (155)
- Volume 13, 2020 (72)
- Volume 12, 2019 (34)
- Volume 11, 2018 (24)
- Volume 10, 2017 (31)
- Volume 9, 2016 (14)
- Volume 8, 2015 (16)
- Volume 7, 2014 (37)
- Volume 6, 2013 (15)
- Volume 5, 2012 (12)
- Volume 4, 2011 (10)
- Volume 3, 2010 (11)
- Volume 2, 2009 (9)
- Volume 1, 2008 (2)
Archive: Volume 12, 2019
CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese
Chow E, Poon EWM, Fok BSP, Chan JCN, Tomlinson B
Pharmacogenomics and Personalized Medicine 2019, 12:397-401
Published Date: 3 January 2020
Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
Bai W, Wang H, Bai H
Pharmacogenomics and Personalized Medicine 2019, 12:387-396
Published Date: 3 January 2020
Evaluation of Hematological Parameters in the Genetic Prospective in Epileptic Patients of Khyber Pakhtunkhwa
Farooq N, Ali N, Ullah S
Pharmacogenomics and Personalized Medicine 2019, 12:377-385
Published Date: 23 December 2019
Individualized Drug Repositioning For Rheumatoid Arthritis Using Weighted Kolmogorov–Smirnov Algorithm
Hu RY, Tian XB, Li B, Luo R, Zhang B, Zhao JM
Pharmacogenomics and Personalized Medicine 2019, 12:369-375
Published Date: 11 December 2019
OPRM1 A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches
Taqi MM, Faisal M, Zaman H
Pharmacogenomics and Personalized Medicine 2019, 12:361-368
Published Date: 27 November 2019
Pharmacogenomics And Hypertension: Current Insights
Oliveira-Paula GH, Pereira SC, Tanus-Santos JE, Lacchini R
Pharmacogenomics and Personalized Medicine 2019, 12:341-359
Published Date: 22 November 2019
Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects
Dorofeeva MN, Shikh EV, Sizova ZM, Tarasenko AV, Denisenko NP, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA, Sychev DA
Pharmacogenomics and Personalized Medicine 2019, 12:329-339
Published Date: 5 November 2019
A Novel Mutation Of The EMD Gene In A Family With Cardiac Conduction Abnormalities And A High Incidence Of Sudden Cardiac Death
Kong D, Zhan Y, Liu C, Hu Y, Zhou Y, Luo J, Gu L, Zhou X, Zhang Z
Pharmacogenomics and Personalized Medicine 2019, 12:319-327
Published Date: 31 October 2019
Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare
Giri J, Moyer AM, Bielinski SJ, Caraballo PJ
Pharmacogenomics and Personalized Medicine 2019, 12:305-318
Published Date: 30 October 2019
Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy
Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y
Pharmacogenomics and Personalized Medicine 2019, 12:297-303
Published Date: 21 October 2019
The AKR1D1*36 (rs1872930) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome
Kapedanovska-Nestorovska A, Dimovski AJ, Sterjev Z, Matevska Geskovska N, Suturkova L, Ugurov P, Mitrev Z, Rosalia R
Pharmacogenomics and Personalized Medicine 2019, 12:287-295
Published Date: 21 October 2019
Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges
Haga SB
Pharmacogenomics and Personalized Medicine 2019, 12:273-285
Published Date: 14 October 2019
Diversity In Precision Medicine And Pharmacogenetics: Methodological And Conceptual Considerations For Broadening Participation
Popejoy AB
Pharmacogenomics and Personalized Medicine 2019, 12:257-271
Published Date: 14 October 2019
Knowledge And Attitudes Of Pharmacy Students Towards Pharmacogenomics Among Universities In Jordan And West Bank Of Palestine
Jarrar Y, Mosleh R, Hawash M, Jarrar Q
Pharmacogenomics and Personalized Medicine 2019, 12:247-255
Published Date: 7 October 2019
Personalized treatment options for thyroid cancer: current perspectives
Khatami F, Larijani B, Nikfar S, Hasanzad M, Fendereski K, Tavangar SM
Pharmacogenomics and Personalized Medicine 2019, 12:235-245
Published Date: 13 September 2019
Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study
AL-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Al-Quasmi MN, Aljamal HA
Pharmacogenomics and Personalized Medicine 2019, 12:225-233
Published Date: 4 September 2019
Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia
Yaowaluk T, Senanarong V, Limwongse C, Boonprasert R, Kijsanayotin P
Pharmacogenomics and Personalized Medicine 2019, 12:209-224
Published Date: 4 September 2019
The influence of an IL-4 variable number tandem repeat (VNTR) polymorphism on breast cancer susceptibility
AL-Eitan LN, Rababa'h DM, Alghamdi MA, Khasawneh RH
Pharmacogenomics and Personalized Medicine 2019, 12:201-207
Published Date: 26 August 2019
Toxicogenomic analysis of publicly available transcriptomic data can predict food, drugs, and chemical-induced asthma
Hachim MY, Hachim IY, Elemam NM, Hamoudi RA
Pharmacogenomics and Personalized Medicine 2019, 12:181-199
Published Date: 26 August 2019
A personalized approach to acute myeloid leukemia therapy: current options
Illangeswaran RSS, Das S, Paul DZ, Mathews V, Balasubramanian P
Pharmacogenomics and Personalized Medicine 2019, 12:167-179
Published Date: 2 August 2019
Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia
Puangpetch A, Srisawasdi P, Unaharassamee W, Jiratjintana N, Vanavanan S, Punprasit S, Na Nakorn C, Sukasem C, Kroll MH
Pharmacogenomics and Personalized Medicine 2019, 12:155-166
Published Date: 6 August 2019
Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery
Awad H, Ahmed A, Urman RD, Stoicea N, Bergese SD
Pharmacogenomics and Personalized Medicine 2019, 12:145-154
Published Date: 26 July 2019
Update on the pharmacogenomics of pain management
Kaye AD, Garcia AJ, Hall OM, Jeha GM, Cramer KD, Granier AL, Kallurkar A, Cornett EM, Urman RD
Pharmacogenomics and Personalized Medicine 2019, 12:125-143
Published Date: 3 July 2019
Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications
Zhang F, Finkelstein J
Pharmacogenomics and Personalized Medicine 2019, 12:107-123
Published Date: 2 July 2019
Plasma brain-derived neurotrophic factor (BDNF) concentration and the BDNF Val66Met polymorphism in suicide: a prospective study in patients with depressive disorder
Ai M, Wang J, Chen J, Wang W, Xu X, Gan Y, Li X, Gou X, Cao J, Lv Z, Chen X, Wang H, Ma Q, Kuang L
Pharmacogenomics and Personalized Medicine 2019, 12:97-106
Published Date: 2 July 2019
Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients
AL-Eitan LN, Al-Dalalah IM, Mustafa MM, Alghamdi MA, Elshammari AK, Khreisat WH, Aljamal HA
Pharmacogenomics and Personalized Medicine 2019, 12:87-95
Published Date: 10 June 2019
g-Nomic: a new pharmacogenetics interpretation software
Sabater A, Ciudad CJ, Cendros M, Dobrokhotov D, Sabater-Tobella J
Pharmacogenomics and Personalized Medicine 2019, 12:75-85
Published Date: 29 May 2019
Personalized medicine in breast cancer: pharmacogenomics approaches
Jeibouei S, Akbari ME, Kalbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H
Pharmacogenomics and Personalized Medicine 2019, 12:59-73
Published Date: 27 May 2019
VKORC1 variants as significant predictors of warfarin dose in Emiratis
Al-Mahayri ZN, Al Jaibeji HS, Saab Y, Soliman K, Al-Gazali L, Patrinos GP, Ali BR
Pharmacogenomics and Personalized Medicine 2019, 12:47-57
Published Date: 17 April 2019
Identification of genetic variants associated with skeletal muscle function deficit in childhood acute lymphoblastic leukemia survivors
Nadeau G, Ouimet-Grennan E, Aaron M, Drouin S, Bertout L, Shalmiev A, Beaulieu P, St-Onge P, Veilleux LN, Rauch F, Petrykey K, Laverdière C, Sinnett D, Alos N, Krajinovic M
Pharmacogenomics and Personalized Medicine 2019, 12:33-45
Published Date: 11 April 2019
Population’s perspectives toward biobanks in scientific research: a study from Jordan
Makhlouf H, Alrabadi N, Khabour OF, Alzoubi KH, Al-Delaimy W
Pharmacogenomics and Personalized Medicine 2019, 12:23-32
Published Date: 21 March 2019
Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease
AL-Eitan LN, Almasri AY, Al-Habahbeh SO
Pharmacogenomics and Personalized Medicine 2019, 12:15-22
Published Date: 21 March 2019
Precision medicine approaches for the management of Ewing sarcoma: current perspectives
Rizk VT, Walko CM, Brohl AS
Pharmacogenomics and Personalized Medicine 2019, 12:9-14
Published Date: 17 January 2019
Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
AL-Eitan LN, Almasri AY, Al-Habahbeh SO
Pharmacogenomics and Personalized Medicine 2019, 12:1-8
Published Date: 14 January 2019